Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tracy Todd Batchelor, M.D.

Co-Author

This page shows the publications co-authored by Tracy Batchelor and Scott Plotkin.
Connection Strength

3.567
  1. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004 Sep 01; 10(17):5643-6.
    View in: PubMed
    Score: 0.310
  2. Primary nervous system lymphoma. Curr Treat Options Oncol. 2002 Dec; 3(6):525-35.
    View in: PubMed
    Score: 0.275
  3. Primary nervous-system lymphoma. Lancet Oncol. 2001 Jun; 2(6):354-65.
    View in: PubMed
    Score: 0.247
  4. Advances in the therapy of primary central nervous system lymphoma. Clin Lymphoma. 2001 Mar; 1(4):263-75; discussion 276-7.
    View in: PubMed
    Score: 0.243
  5. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.231
  6. Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clin Cancer Res. 2020 01 01; 26(1):206-212.
    View in: PubMed
    Score: 0.220
  7. Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. NPJ Precis Oncol. 2017; 1(1):33.
    View in: PubMed
    Score: 0.191
  8. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.188
  9. Glioblastoma care in the elderly. Cancer. 2016 Jan 15; 122(2):189-97.
    View in: PubMed
    Score: 0.169
  10. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12.
    View in: PubMed
    Score: 0.153
  11. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
    View in: PubMed
    Score: 0.146
  12. Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol. 2011 Mar 01; 29(7):e159-62.
    View in: PubMed
    Score: 0.120
  13. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32.
    View in: PubMed
    Score: 0.118
  14. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010 Sep; 31(7):1135-43.
    View in: PubMed
    Score: 0.117
  15. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
    View in: PubMed
    Score: 0.115
  16. Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2035.
    View in: PubMed
    Score: 0.107
  17. Treatment of progressive neurofibromatosis type 2-related vestibular schwannoma with erlotinib. J Clin Oncol. 2008 May 20; 26(15_suppl):2045.
    View in: PubMed
    Score: 0.100
  18. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
    View in: PubMed
    Score: 0.091
  19. Peripheral and cranial nerve sheath tumors. Curr Opin Neurol. 2005 Oct; 18(5):604-10.
    View in: PubMed
    Score: 0.084
  20. Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2019 Jun 14; 9(1):8721.
    View in: PubMed
    Score: 0.054
  21. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2018 11 20; 8(1):17062.
    View in: PubMed
    Score: 0.052
  22. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
    View in: PubMed
    Score: 0.040
  23. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan; 17(1):116-21.
    View in: PubMed
    Score: 0.039
  24. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87.
    View in: PubMed
    Score: 0.036
  25. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5.
    View in: PubMed
    Score: 0.035
  26. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040.
    View in: PubMed
    Score: 0.031
  27. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 01; 71(1):19-28.
    View in: PubMed
    Score: 0.030
  28. Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment. J Clin Oncol. 2008 May 20; 26(15_suppl):2009.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.